At its meeting on 08 August 2022 the Transparency Council adopted Opinion No. 122/2022 on the inclusion in the drug reimbursement procedure of medicines containing the active substance etanercept as regards indications for use or posology or route of administration other than those specified in the Summary of Product Characteristics, i.e. treatment of peripheral SpA.